Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings
Mentor Ali Ber Lucien, Pilar Ramón-Pardo(World Health Organization Regional Office for the Americas), Gina Maki(Henry Ford Health System), Manise Pierre, Marcus Zervos(Henry Ford Health System), Patrick Dély, Natael Fénélon, Michael F. Canarie(Yale University), Gladzdin Jean-Denis, Mauricio Cerpa, Hatim Sati(World Health Organization), Gérard Joseph, Paul E. Kilgore(Eugene Applebaum College of Pharmacy and Health Sciences), Ana del Rı́o(World Health Organization Regional Office for the Americas), Jacques Boncy
Cited by 256
Related Papers
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
|Journal of Clinical Microbiology|1994|508
Trends in US Hospital Admissions for Skin and Soft Tissue Infections
|Emerging infectious diseases|2009|327